SCHEMBL5204968

SCHEMBL5204968

COc1cc(I)cc(OC)c1OCCO

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TUBB1 Q9H4B7 3/20 0.46
TSHR P16473 1/20 0.44
L3MBTL1 Q9Y468 1/20 0.44
SMN1; SMN2 Q16637 2/20 0.42
DHPS P49366 3/20 0.42
BRD4 O60885 2/20 0.42
BPTF Q12830 1/20 0.41
MAPK1 P28482 1/20 0.39
CYP3A4 P08684 1/20 0.38
MAPT P10636 1/20 0.38
MGAM O43451 1/20 0.37
GAA P10253 1/20 0.37
SI P14410 1/20 0.37
MGAM2 Q2M2H8 1/20 0.37
TUBB4A P04350 1/20 0.36
TUBB P07437 1/20 0.36
TUBA3C P0DPH7 1/20 0.36
TUBA1B P68363 1/20 0.36
TUBA4A P68366 1/20 0.36
TUBB4B P68371 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1883751 0.84 KDM4E (0.49) TUBB1DHPSBRD4BPTF
SCHEMBL5208622 0.82 TNFRSF1A (0.47) L3MBTL1SMN1; SMN2MAPK1MAPTSYK
SCHEMBL1327532 0.81 TUBB1 (0.46) TUBB1TSHRL3MBTL1SMN1; SMN2DHPS
SCHEMBL2744248 0.81 TSHR (0.50) TUBB1TSHRL3MBTL1SMN1; SMN2BRD4
SCHEMBL2744232 0.80 TUBB1 (0.54) TUBB1TSHRL3MBTL1SMN1; SMN2BRD4
SCHEMBL7122419 0.79 TUBB1 (0.49) TUBB1TSHRL3MBTL1SMN1; SMN2BPTF
SCHEMBL5208819 0.78 HTR2A (0.56) TUBB1TSHRSMN1; SMN2BPTFMAPT
SCHEMBL15162110 0.77 TTR (0.40) SMN1; SMN2DHPSCYP3A4GAA
SCHEMBL18031322 0.77 TPMT (0.57) TUBB1TSHRL3MBTL1SMN1; SMN2BPTF
SCHEMBL25193508 0.76 HTR1A (0.44) SMN1; SMN2DHPSBRD4CYP3A4GAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1403251-B1 BIS(2-ARYL-5-PYRIDYL) DERIVATIVE KOWA CO (JP) 2007-07-18 EP disclosed
US-6890940-B2 Bis(2-aryl-5-pyridyl) derivatives KOWA CO., LTD. (JP) 2005-05-10 US disclosed
EP-1403251-A1 BIS(2-ARYL-5-PYRIDYL) DERIVATIVE Kowa Co., Ltd. (JP) 2004-03-31 EP disclosed
US-20030022886-A1 Immoglobulin E (IgE) antibody production inhibitor; treating allergic immune diseases such as asthma, dermatitis, inflammatory bowel disease and allergic opthalmopathy KOWA CO., LTD. (JP) 2003-01-30 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030022886-A1 Immoglobulin E (IgE) antibody production inhibitor; treating allergic immune diseases such as asthma, dermatitis, inflammatory bowel disease and allergic opthalmopathy IGLV6-57, IL5, IGSF11 TUBB1 785/4885TSHR 3200/4885L3MBTL1 2687/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.